NEUREN PHARMACEUTICALS LIMITED ANNUAL GENERAL MEETING
Thursday, 29 June, 2017
RESULT OF GENERAL MEETING (ASX REPORT)As required by section 251AA(2) of the Corporations Act 2001 (Commonwealth) the following statistics are provided in respect of each resolution on the agenda.
Manner in which the securityholder directed the proxy vote (as at proxy close): | Manner in which votes were cast in person or by proxy on a poll (where applicable) | ||||||
Resolution | Votes For | Votes Against | Votes Discretionary | Votes Abstain | For | Against | Abstain ** |
1 RE-ELECT BRUCE HANCOX AS A DIRECTOR OF THE COMPANY | 704,726,846 | 1,688,550 | 6,798,365 | 585,000 | Passed on a show of hands | Passed on a show of hands | Passed on a show of hands |
2 RE-APPOINTMENT OF PRICEWATERHOUSECOOPERS AS THE AUDITOR | 704,872,396 | 46,000 | 6,805,365 | 2,075,000 | Passed on a show of hands | Passed on a show of hands | Passed on a show of hands |
** - Note that votes relating to a person who abstains on an item are not counted in determining whether or not the required majority of votes were cast for or against that item
Printed: 29/06/2017 10:33:20AM
This report was produced from the Link Market Services System
Page 1 of 1
Neuren Pharmaceuticals Limited published this content on 29 June 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 29 June 2017 03:14:08 UTC.
Original documenthttp://www.neurenpharma.com/irm/PDF/1681_0/ResultsofMeeting
Public permalinkhttp://www.publicnow.com/view/8B9699AFFD08EBDC53B7C7B3BF7CD368B73B7403
